McCracken, D Jay <br/><br/>
Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.  [electronic resource] 

 -  Journal of neuro-oncology  10 2016 
 - 193-201 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1573-7373 
<br/><br/><label>Standard No.: </label>10.1007/s11060-016-2234-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Agents--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab--therapeutic use<br/>Bortezomib--therapeutic use<br/>Brain Neoplasms--drug therapy<br/>Dacarbazine--analogs & derivatives<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Glioblastoma--drug therapy<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Retrospective Studies<br/>Temozolomide